心肌梗死(MI),包括ST段抬高MI(STEMI)和非ST段抬高MI(NSTEMI),仍然是全球死亡的主要原因。代谢组学技术用于探索差异代谢物(DMs)作为潜在的生物标志物,用于早期诊断STEMI和NSTEMI。在研究中,2531种代谢物,包括1925年的DM,被发现了。在选定的27个DM中,14人在一个新的队列中成功验证,AUC值均在0.8以上。STEMI组有10人,即L-天冬氨酸,L-乙酰肉碱,乙酰甘氨酸,癸基肉碱,羟基苯基乳酸,阿魏酸,衣康酸,月桂酰肉碱,肉豆蔻酰基肉碱,顺式-4-羟基-D-脯氨酸,NSTEMI组5名,即L-天冬氨酸,花生四烯酸,棕榈油酸,D-天冬氨酸,和棕榈酸.这14种DM可作为早期诊断MI的生物标志物,具有高灵敏度和特异性。这些发现对于NSTEMI患者具有特别重要的临床意义,因为这些患者没有典型的ECG变化。
Myocardial infarction (MI), including ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI), is still a leading cause of death worldwide. Metabolomics technology was used to explore differential metabolites (DMs) as potential biomarkers for early diagnosis of STEMI and NSTEMI. In the study, 2531 metabolites, including 1925 DMs, were discovered. In the selected 27 DMs, 14 were successfully verified in a new cohort, and the AUC values were all above 0.8. There were 10 in STEMI group, namely L-aspartic acid, L-acetylcarnitine, acetylglycine, decanoylcarnitine, hydroxyphenyllactic acid, ferulic acid, itaconic acid, lauroylcarnitine, myristoylcarnitine, and cis-4-hydroxy-D-proline, and 5 in NSTEMI group, namely L-aspartic acid, arachidonic acid, palmitoleic acid, D-aspartic acid, and palmitelaidic acid. These 14 DMs may be developed as biomarkers for the early diagnosis of MI with high sensitivity and specificity. These findings have particularly important clinical significance for NSTEMI patients because these patients have no typical ECG changes.